DOUGLAS R. ROSING, M.D.; STEPHEN E. EPSTEIN, M.D.
This content is PDF only. Please click on the PDF icon to access.
For many years beta-adrenergic receptor blocking agents have been the primary pharmacologic agents for treating patients with hypertrophic cardiomyopathy (1, 2). The beneficial hemodynamic and symptomatic effects produced by these drugs are derived from their inhibition of sympathetic stimulation to the heart (3). Until recently, if beta blocker therapy failed to provide a satisfactory therapeutic response in patients with left ventricular outflow tract obstruction, an operation was done to control symptoms, usually a ventricular septal myotomy-myectomy.
Several studies, however, have shown that administering verapamil, the prototype calcium-channel blocking agent, to patients with hypertrophic cardiomyopathy can reduce left ventricular outflow tract
ROSING DR, EPSTEIN SE. Verapamil in the Treatment of Hypertrophic Cardiomyopathy. Ann Intern Med. ;96:670–672. doi: 10.7326/0003-4819-96-5-670
Download citation file:
Published: Ann Intern Med. 1982;96(5):670-672.
Cardiology, Coronary Risk Factors, HIV, Hypertension, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use